Charles Makin

467 total citations
26 papers, 397 citations indexed

About

Charles Makin is a scholar working on Pediatrics, Perinatology and Child Health, Rheumatology and Psychiatry and Mental health. According to data from OpenAlex, Charles Makin has authored 26 papers receiving a total of 397 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pediatrics, Perinatology and Child Health, 6 papers in Rheumatology and 6 papers in Psychiatry and Mental health. Recurrent topics in Charles Makin's work include Rheumatoid Arthritis Research and Therapies (6 papers), Multiple Sclerosis Research Studies (5 papers) and Autoimmune and Inflammatory Disorders Research (4 papers). Charles Makin is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (6 papers), Multiple Sclerosis Research Studies (5 papers) and Autoimmune and Inflammatory Disorders Research (4 papers). Charles Makin collaborates with scholars based in United States, Switzerland and France. Charles Makin's co-authors include Allison Petrilla, Neetu Agashivala, Raquel Lahoz, Catherine B. McGuiness, Jonathan R. Korn, Swapna Karkare, Niklas Bergvall, Gorana Capkun, Ashish Pradhan and Alexandros Sagkriotis and has published in prestigious journals such as PLoS ONE, Neurology and Annals of the Rheumatic Diseases.

In The Last Decade

Charles Makin

26 papers receiving 386 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Charles Makin United States	10	169	86	65	53	50	26	397
Nela Krosnjar United States	5	54 0.3×	66 0.8×	88 1.4×	49 0.9×	40 0.8×	13	430
Padmanabha Shenoy India	9	169 1.0×	123 1.4×	55 0.8×	33 0.6×	47 0.9×	42	472
Cecilia Ridaura Mexico	13	119 0.7×	38 0.4×	31 0.5×	191 3.6×	33 0.7×	20	520
Pedro de Alarcón United States	13	100 0.6×	36 0.4×	73 1.1×	101 1.9×	129 2.6×	25	530
Chengappa Kavadichanda India	13	50 0.3×	231 2.7×	80 1.2×	41 0.8×	34 0.7×	62	521
M. Weyl Ben Arush Israel	11	46 0.3×	27 0.3×	32 0.5×	112 2.1×	100 2.0×	21	417
Nirmalya Roy Moulik India	12	26 0.2×	54 0.6×	61 0.9×	68 1.3×	156 3.1×	57	385
Mathew Alexander India	13	88 0.5×	57 0.7×	12 0.2×	18 0.3×	56 1.1×	39	440
Russell As Canada	13	65 0.4×	267 3.1×	47 0.7×	23 0.4×	45 0.9×	41	472
Nancy Eby United States	10	358 2.1×	50 0.6×	51 0.8×	246 4.6×	53 1.1×	15	772

Countries citing papers authored by Charles Makin

Since Specialization

Citations

This map shows the geographic impact of Charles Makin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles Makin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles Makin more than expected).

Fields of papers citing papers by Charles Makin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles Makin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles Makin. The network helps show where Charles Makin may publish in the future.

Co-authorship network of co-authors of Charles Makin

This figure shows the co-authorship network connecting the top 25 collaborators of Charles Makin. A scholar is included among the top collaborators of Charles Makin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charles Makin. Charles Makin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Reder, Anthony T., et al.. (2021). Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders. 51. 102935–102935. 4 indexed citations

Sikirica, Vanja, Per Gustafsson, & Charles Makin. (2017). Treatment Patterns among Children and Adolescents with Attention-Deficit/Hyperactivity Disorder with or without Psychiatric or Neurologic Comorbidities in Sweden: A Retrospective Cohort Study. Neurology and Therapy. 6(1). 115–130. 2 indexed citations

Gerber, Robert A., et al.. (2017). Tofacitinib versus Biologic Treatments in Moderate-to-Severe Rheumatoid Arthritis Patients Who Have Had an Inadequate Response to Nonbiologic DMARDs: Systematic Literature Review and Network Meta-Analysis. International Journal of Rheumatology. 2017. 1–15. 26 indexed citations

Asche, Carl V., et al.. (2016). Evaluation of Resource Utilization and Treatment Patterns in Patients with Actinic Keratosis in the United States. Value in Health. 19(2). 239–248. 8 indexed citations

Sikirica, Vanja, et al.. (2016). Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in Germany. The European Journal of Health Economics. 18(7). 893–904. 4 indexed citations

McGuiness, Catherine B., et al.. (2015). Incidence of Ischemic Colitis in Treated, Commercially Insured Hypertensive Adults: A Cohort Study of US Health Claims Data. American Journal of Cardiovascular Drugs. 15(2). 135–149. 2 indexed citations

Lyu, R., Qian Ding, Christopher M. Black, et al.. (2015). Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany. Rheumatology International. 36(1). 143–153. 23 indexed citations

Ferreira, Alberto, et al.. (2015). Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA. PLoS ONE. 10(7). e0133968–e0133968. 51 indexed citations

Divino, Victoria, Allison Petrilla, Vamsi Bollu, et al.. (2015). Clinical and economic burden of breakthrough seizures. Epilepsy & Behavior. 51. 40–47. 22 indexed citations

10.

Durgin, Tracy, et al.. (2015). Lacosamide Monotherapy Treatment Pathways in Epilepsy Patients in a US Managed Care Population (P3.201). Neurology. 84(14_supplement). 1 indexed citations

11.

DeKoven, Mitch, et al.. (2015). Economic Burden of HIV Antiretroviral Therapy Adverse Events in the United States. Journal of the International Association of Providers of AIDS Care (JIAPAC). 15(1). 66–76. 9 indexed citations

12.

Makin, Charles, et al.. (2014). Non-adherence to Antiplatelet Therapy After Hospitalization for Acute Coronary Syndrome (Acs) Increases Readmissions, Mortality, Health Care Use and Costs. Value in Health. 17(3). A8–A8. 1 indexed citations

13.

Makin, Charles, Allison Petrilla, Victoria Divino, et al.. (2014). Comparison of Health Care Resource Utilization and Costs in Treatment-Adherent Patients with Epilepsy with and without Breakthrough Seizures in A U.S. Managed Care Population (P5.069). Neurology. 82(10_supplement). 1 indexed citations

14.

Bergvall, Niklas, Allison Petrilla, Swapna Karkare, et al.. (2014). Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis. Journal of Medical Economics. 17(10). 696–707. 79 indexed citations

15.

Divino, Victoria, Allison Petrilla, Vamsi Bollu, et al.. (2014). Real-World Persistence and Treatment Failure Associated with First Line Use of Antiepileptic Drug Treatment in a Large U.S. Managed Care Population (P5.072). Neurology. 82(10_supplement). 4 indexed citations

16.

Bergvall, Niklas, Charles Makin, Raquel Lahoz, et al.. (2014). Relapse Rates in Patients with Multiple Sclerosis Switching from Interferon to Fingolimod or Glatiramer Acetate: A US Claims Database Study. PLoS ONE. 9(2). e88472–e88472. 58 indexed citations

17.

Lahoz, Raquel, Niklas Bergvall, Neetu Agashivala, et al.. (2014). Relapse Rates Among Patients With Multiple Sclerosis Who Switch From Interferon Therapy To Fingolimod Or Glatiramer Acetate: A Retrospective US Claims Database Analysis (P7.211). Neurology. 82(10_supplement). 6 indexed citations

18.

Bergvall, Niklas, Charles Makin, Raquel Lahoz, et al.. (2013). Comparative effectiveness of fingolimod versus interferons or glatiramer acetate for relapse rates in multiple sclerosis: a retrospective US claims database analysis. Current Medical Research and Opinion. 29(12). 1647–1656. 35 indexed citations

19.

Singhal, Puneet K., et al.. (2011). Work and productivity loss related to herpes zoster. Journal of Medical Economics. 14(5). 639–645. 26 indexed citations

20.

Delea, Thomas E., Manjusha Gokhale, Charles Makin, et al.. (2007). Administrative Claims Analysis of Utilization and Costs of Care in Health Plan Members With Atopic Dermatitis Who Had Prior Use of a Topical Corticosteroid and Who Initiate Therapy With Pimecrolimus or Tacrolimus. Journal of Managed Care Pharmacy. 13(4). 349–359. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact